Anaemia in older people with chronic heart failure: The potential cost

Technology and Health Care

Volumn 17, Issue 5-6, 2009, Pages 377-385

  Man Fai Sim, Victor ^a   Nam, Michael Chi Yuen Yuen ^b   Riley, Steve ^c   Yousef, Zaheer ^c   Hurley, Joanna ^b   Cheung, Wai Yee ^d   O'Mahony, Sinead ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b LLANDOUGH HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^d SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

Anaemia; Chronic heart failure; Chronic kidney disease; Costs; Erythropoiesis stimulating agents; Intravenous iron

Indexed keywords

ANTIANEMIC AGENT; IRON;

AGE; AGED; ANEMIA; ARTICLE; CHRONIC DISEASE; CHRONIC KIDNEY FAILURE; COST; ECONOMICS; FEMALE; HEART FAILURE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PREVALENCE; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; TEACHING HOSPITAL;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANEMIA; CHRONIC DISEASE; COSTS AND COST ANALYSIS; FEMALE; HEART FAILURE; HEMATINICS; HOSPITALS, TEACHING; HUMANS; INJECTIONS, INTRAVENOUS; IRON; KIDNEY FAILURE, CHRONIC; MALE; PREVALENCE; SENSITIVITY AND SPECIFICITY; SEX FACTORS;

EID: 77049123456     PISSN: 09287329     EISSN: None     Source Type: Journal    
DOI: 10.3233/THC-2009-0557     Document Type: Article

References (28)

1. L. Beck-da-Silva, L.E. Rohde, A.C. Pereira-Barretto et al., Rationale and design of the IRON-HF study: a randomized trial to assess the effects of iron supplementation in heart failure patients with anemia, J Card Fail 13 (2007), 14-17.
2. A.P. Bolger, F.R. Bartlett, H.S. Penston et al., Intravenous iron alone for the treatment of anemia in patients with chronic heart failure, J Am Coll Cardiol 48 (2006), 1225-1227.
3. M.J. Calvert , N. Freemantle, G. Yao et al., CARE-HF investigators, Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial, Eur Heart J 26 (2005), 2681-2688.
4. CIBIS-II Investigators and Health Economics Group: Reduced costs with bisoprolol treatment for heart failure: an economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS-II), Eur Heart J 22 (2001), 1021-1031.
5. J.G.F. Cleland, J.C. Daubert, E. Erdmann et al., The effect of cardiac resynchronization on morbidity and mortality in heart failure, N Engl J Med 352 (2005), 1539-1549.
6. M.R. Cowie, D.A.Wood, A.J. Coats et al., Incidence and aetiology of heart failure; a population-based study, Eur Heart J 20 (1999), 421-428.
7. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology, Eur Heart J 29 (2008), 2388-2442.
8. A.F. Goddard, M. W. James and A.S. McIntyre, Guidelines for the management of iron deficiency anaemia, BSG Guidelines in Gastroenterology (May 2005).
9. S.F. Ho, M.S. O'Mahony, J.A. Steward et al., Left ventricular systolic dysfunction and atrial fibrillation in older people in the community-a need for screening? Age Ageing 33 (2004), 488-492.
10. T.B. Horwich, G.C. Fonarow, M.A. Hamilton et al., Anaemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure, J Am Coll Cardiol 11 (2002), 1780-1786.
11. S.A. Hunt, W.T. Abraham, M.H. Chin et al., American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society, Circulation 112 (2005), e154-e235.
12. P.R. Kalra, T. Collier, M.R. Cowie et al., Haemoglobin concentration and prognosis in new cases of heart failure, Lancet 362 (2003), 211-212.
13. M. Kosiborod, G.L. Smith, M.J. Radford et al., The prognostic importance of anemia in patients with heart failure, Am J Med 114 (2003), 112-119.
14. P. Lechat, K.W. Brunhuber, R. Hofmann et al., The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial, Lancet 353 (1999), 9-13. (Pubitemid 29037695)
15. F. Locatelli, P. Aljama, P. Barany et al., European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure, Nephrol Dial Transplant 19 Suppl (2004), 1-47.
16. T.A. McDonagh, C.E. Morrison, A. Lawrence et al., Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population, Lancet 350 (1997), 829-833.
17. National Institute of Clinical Excellence (NICE), CG39 Anaemia management in people with Chronic Kidney Disease: Full Guideline, September 2006.
18. National Institute of Clinical Excellence: CG39 National costing report: anaemia management in people with CKD, September 2006.
19. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification, Am J Kidney Dis 39 Suppl (2002), S1-S266.
20. National Statistics office. http://www.statistics.gov.uk/census2001/ census2001.asp.
21. A. Palazzuoli, D. Silverberg, F. Iovine et al., Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia, Am Heart J 152 (2006), e9-e15.
22. P. Ponikowski, S.D. Anker, J. Szachniewicz et al., Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial, J Am Coll Cardiol 49 (2007), 753-762. (Pubitemid 46240705)
23. D.S. Silverberg, D. Wexler, M. Blum et al., The Effect of Correction of Mild Anaemia in Severe, Resistant Congestive Heart Failure Using Subcutaneous Erythropoietin and Intravenous Iron; A Randomised Controlled Study, J Am Coll Cardiol 37 (2001), 1775-1780.
24. D.S. Silverberg, D.Wexler,M. Blum et al., The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function, functional cardiac class, and markedly reduces hospitalizations, J Am Coll Cardiol 35 (2000), 1737-1744.
25. D.S. Silverberg, D.Wexler, M. Blum and A. Iaina, The cardio renal anemia syndrome: correcting anemia inpatients with resistant congestive heart failure can improve both cardiac and renal function and reduces hospitalization, Clin Nephrol 60(Suppl 1) (2003), S93-S102.
26. World Health Organization/United Nations University/UNICEF, Iron deficiency anaemia, assessment, prevention and control: a guide for programme managers, Geneva, WHO, 2001.
27. G. Yao, N. Freemantle, M.J. Calvert et al., The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator, Eur Heart J 28 (2007), 42-51.
28. J.B. Young, I.S. Anand, R. Diaz et al., Reduction of events with darbepoetin alfa in Heart Failure (RED-HF) Trial (abstract), J Card Fail 12 (Suppl 1) (2006), S77.